Title:
NOVEL ANTI-PAD4 ANTIBODY
Document Type and Number:
WIPO Patent Application WO/2022/176970
Kind Code:
A1
Abstract:
Provided is an anti-PAD4 antibody in which HCDR1 includes an amino acid sequence of SEQ ID NO: 1, HCDR2 includes an amino acid sequence of SEQ ID NO: 2, HCDR3 includes an amino acid sequence of SEQ ID NO: 3, LCDR1 includes an amino acid sequence of SEQ ID NO: 4, LCDR2 includes an amino acid sequence of SEQ ID NO: 5, and LCDR3 includes an amino acid sequence of SEQ ID NO: 6, or an antibody fragment thereof.
More Like This:
Inventors:
MIYAMOTO YUYA (JP)
WADA KOICHI (JP)
IMURA YUICHI (JP)
SAITO KENJI (JP)
SAKATA TOMOKO (JP)
SHIGEMITSU TAKANARI (JP)
WADA KOICHI (JP)
IMURA YUICHI (JP)
SAITO KENJI (JP)
SAKATA TOMOKO (JP)
SHIGEMITSU TAKANARI (JP)
Application Number:
PCT/JP2022/006528
Publication Date:
August 25, 2022
Filing Date:
February 18, 2022
Export Citation:
Assignee:
MITSUBISHI TANABE PHARMA CORP (JP)
PHARMA FOODS INT CO LTD (JP)
PHARMA FOODS INT CO LTD (JP)
International Classes:
C12N15/13; A61K39/395; A61P13/12; A61P19/02; A61P29/00; A61P37/02; A61P37/06; A61P43/00; C07K16/40; C12N1/15; C12N1/19; C12N1/21; C12N5/10
Domestic Patent References:
| WO2016143753A1 | 2016-09-15 | |||
| WO2012026309A1 | 2012-03-01 | |||
| WO2016143753A1 | 2016-09-15 | |||
| WO1994025585A1 | 1994-11-10 | |||
| WO2005035586A1 | 2005-04-21 | |||
| WO2002031140A1 | 2002-04-18 | |||
| WO2000061739A1 | 2000-10-19 | |||
| WO2016175236A1 | 2016-11-03 | |||
| WO2003018056A1 | 2003-03-06 |
Foreign References:
| JP2011507519A | 2011-03-10 | |||
| JP2008536490A | 2008-09-11 | |||
| JP2007526756A | 2007-09-20 | |||
| JPH04506458B1 | ||||
| JP2912618B2 | 1999-06-28 | |||
| JPH04504365B1 | ||||
| JPH07509137B1 | ||||
| JPH06500233B1 | ||||
| US6737056B1 | 2004-05-18 | |||
| US7297775B2 | 2007-11-20 | |||
| US7317091B2 | 2008-01-08 | |||
| US4737456A | 1988-04-12 |
Other References:
FUJINO YASUHIRO, FUJITA RISAKO, WADA KOUICHI, FUJISHIGE KOTOMI, KANAMORI TAKASHI, HUNT LINDSEY, SHIMIZU YOSHIHIRO, UEDA TAKUYA: "Robust in vitro affinity maturation strategy based on interface-focused high-throughput mutational scanning", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM NL, vol. 428, no. 3, 1 November 2012 (2012-11-01), Amsterdam NL , pages 395 - 400, XP055960437, ISSN: 0006-291X, DOI: 10.1016/j.bbrc.2012.10.066
SUZUKI ET AL.: "Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis", NAT GENET, vol. 34, no. 4, August 2003 (2003-08-01), pages 395 - 402, XP002979063, DOI: 10.1038/ng1206
ISHIGAMI ET AL.: "Two novel sandwich ELISAs identify PAD4 levels and PAD4 autoantibodies in patients with rheumatoid arthritis", MOD RHEUMATOL, vol. 23, no. 4, July 2013 (2013-07-01), pages 794 - 803, XP055964718, DOI: 10.3109/s10165-012-0748-0
YUDONG ET AL.: "Peptidylarginine deiminases 2 and 4 modulate innate and adaptive immune responses in TLR-7-dependent lupus", JCI INSIGHT, vol. 3, no. 23, 6 December 2018 (2018-12-06), pages 6124729
HANATA ET AL.: "Peptidylarginine Deiminase 4 Promotes the Renal Infiltration of Neutrophils and Exacerbates the TLR7 Agonist-Induced Lupus Mice", FRONT IMMUNOL, vol. 11, 23 June 2020 (2020-06-23), pages 1095
KNIGHT ET AL.: "Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice", ANN RHEUM DIS, vol. 74, no. 12, December 2015 (2015-12-01), pages 2199 - 2206, XP055491990, DOI: 10.1136/annrheumdis-2014-205365
GORDON ET AL.: "Lupus and proliferative nephritis are PAD4 independent in murine models", JCI INSIGHT, vol. 2, no. 10, 18 May 2017 (2017-05-18), pages e92926
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1987, US DEPARTMENT OF HEALTH AND HUMAN SERVICES
"NCBI", Database accession no. NP036519.2
"Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY
ALMAGRO ET AL., FRONT BIOSCI, vol. 13, 1 January 2008 (2008-01-01), pages 1619 - 1633
OZAKI ET AL., BLOOD, vol. 93, no. 11, 1 June 1999 (1999-06-01), pages 3922 - 3930
ROGUSKA ET AL., PROC NATL ACAD SCI USA, vol. 91, no. 3, 1 February 1994 (1994-02-01), pages 969 - 973
DAMSCHRODER ET AL., MOL IMMUNOL, vol. 44, no. 11, 22 January 2007 (2007-01-22), pages 3049 - 3060
RIECHMANN ET AL., NATURE, vol. 332, no. 6162, 24 March 1988 (1988-03-24), pages 323 - 327
NISHIBORI ET AL., MOL IMMUNOL, vol. 43, no. 6, February 2006 (2006-02-01), pages 634 - 42
NATURE GENETICS, vol. 7, 1994, pages 13 - 21
NATURE GENETICS, vol. 15, 1997, pages 146 - 156
NATURE, vol. 368, 1994, pages 856 - 859
NUCLEIC ACIDS RESEARCH, vol. 14, 1986, pages 1779
THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 257, 1982, pages 1516
CELL, vol. 22, 1980, pages 197
WU ET AL., NATURE BIOTECHNOLOGY, vol. 25, no. 11, 2007, pages 1290
KITAZAWA ET AL., NATURE MEDICINE, vol. 18, no. 10, 2012, pages 1570
KENYA SHITARA: "Journal of Pharmacy", vol. 129, 2009, pages: 3
AKIKO ISHII ET AL., JOURNAL OF JAPANESE PHARMACOLOGY, vol. 136, no. 5, 2010, pages 280
SHUHEI HASHIGUCHI ET AL., BIOCHEMISTRY, vol. 82, no. 8, 2010, pages 710
D. J. KING: "Applications and Engineering of Monoclonal antibodies", 1998, T. J. INTERNATIONAL LTD
CHARI ET AL.: "Cancer Res.", vol. 152, 1992, pages: 127
LIU ET AL., PROC NATL ACAD SCI USA., vol. 93, 1996, pages 8681
LIU ET AL.: "Proc Natl Acad Sci USA.", vol. 93, 1996, pages: 8681
FUJINO ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 428, no. 3, 2012, pages 395
FELLOUSE ET AL., J. MOL. BIOL., vol. 373, 2007, pages 924
DICARA ET AL., MABS, vol. 10, no. 7, 2018, pages 1073
PISUPATI ET AL., MABS, vol. 9, no. 7, 2017, pages 1197
SUZUKI ET AL.: "Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis", NAT GENET, vol. 34, no. 4, August 2003 (2003-08-01), pages 395 - 402, XP002979063, DOI: 10.1038/ng1206
ISHIGAMI ET AL.: "Two novel sandwich ELISAs identify PAD4 levels and PAD4 autoantibodies in patients with rheumatoid arthritis", MOD RHEUMATOL, vol. 23, no. 4, July 2013 (2013-07-01), pages 794 - 803, XP055964718, DOI: 10.3109/s10165-012-0748-0
YUDONG ET AL.: "Peptidylarginine deiminases 2 and 4 modulate innate and adaptive immune responses in TLR-7-dependent lupus", JCI INSIGHT, vol. 3, no. 23, 6 December 2018 (2018-12-06), pages 6124729
HANATA ET AL.: "Peptidylarginine Deiminase 4 Promotes the Renal Infiltration of Neutrophils and Exacerbates the TLR7 Agonist-Induced Lupus Mice", FRONT IMMUNOL, vol. 11, 23 June 2020 (2020-06-23), pages 1095
KNIGHT ET AL.: "Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice", ANN RHEUM DIS, vol. 74, no. 12, December 2015 (2015-12-01), pages 2199 - 2206, XP055491990, DOI: 10.1136/annrheumdis-2014-205365
GORDON ET AL.: "Lupus and proliferative nephritis are PAD4 independent in murine models", JCI INSIGHT, vol. 2, no. 10, 18 May 2017 (2017-05-18), pages e92926
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1987, US DEPARTMENT OF HEALTH AND HUMAN SERVICES
"NCBI", Database accession no. NP036519.2
"Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY
ALMAGRO ET AL., FRONT BIOSCI, vol. 13, 1 January 2008 (2008-01-01), pages 1619 - 1633
OZAKI ET AL., BLOOD, vol. 93, no. 11, 1 June 1999 (1999-06-01), pages 3922 - 3930
ROGUSKA ET AL., PROC NATL ACAD SCI USA, vol. 91, no. 3, 1 February 1994 (1994-02-01), pages 969 - 973
DAMSCHRODER ET AL., MOL IMMUNOL, vol. 44, no. 11, 22 January 2007 (2007-01-22), pages 3049 - 3060
RIECHMANN ET AL., NATURE, vol. 332, no. 6162, 24 March 1988 (1988-03-24), pages 323 - 327
NISHIBORI ET AL., MOL IMMUNOL, vol. 43, no. 6, February 2006 (2006-02-01), pages 634 - 42
NATURE GENETICS, vol. 7, 1994, pages 13 - 21
NATURE GENETICS, vol. 15, 1997, pages 146 - 156
NATURE, vol. 368, 1994, pages 856 - 859
NUCLEIC ACIDS RESEARCH, vol. 14, 1986, pages 1779
THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 257, 1982, pages 1516
CELL, vol. 22, 1980, pages 197
WU ET AL., NATURE BIOTECHNOLOGY, vol. 25, no. 11, 2007, pages 1290
KITAZAWA ET AL., NATURE MEDICINE, vol. 18, no. 10, 2012, pages 1570
KENYA SHITARA: "Journal of Pharmacy", vol. 129, 2009, pages: 3
AKIKO ISHII ET AL., JOURNAL OF JAPANESE PHARMACOLOGY, vol. 136, no. 5, 2010, pages 280
SHUHEI HASHIGUCHI ET AL., BIOCHEMISTRY, vol. 82, no. 8, 2010, pages 710
D. J. KING: "Applications and Engineering of Monoclonal antibodies", 1998, T. J. INTERNATIONAL LTD
CHARI ET AL.: "Cancer Res.", vol. 152, 1992, pages: 127
LIU ET AL., PROC NATL ACAD SCI USA., vol. 93, 1996, pages 8681
LIU ET AL.: "Proc Natl Acad Sci USA.", vol. 93, 1996, pages: 8681
FUJINO ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 428, no. 3, 2012, pages 395
FELLOUSE ET AL., J. MOL. BIOL., vol. 373, 2007, pages 924
DICARA ET AL., MABS, vol. 10, no. 7, 2018, pages 1073
PISUPATI ET AL., MABS, vol. 9, no. 7, 2017, pages 1197
Attorney, Agent or Firm:
IP FIRM SHUWA (JP)
Download PDF: